Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
975 GBX | +2.09% | -0.10% | -42.07% |
May. 03 | Jefferies cuts AJ Bell; Deutsche likes ConvaTec | AN |
May. 01 | EXECUTIVE CHANGES: New chairs for CVS Group, LSL Property and Videndum | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company is not the most generous with respect to shareholders' compensation.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-42.07% | 878M | B | ||
-27.47% | 142M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CVSG Stock
- Ratings CVS Group plc